Although it appears that much of CHEK2’s immunomodulating capabilities arise from its role in the DDR pathway, new evidence suggests that CHEK2 may play a novel role in directly altering the immune tumor microenvironment. The gene discussed is CHEK2; the disease is neoplasm.